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Solid Substrate Room-temperature Phosphorescence of 
Phenothiazine and Related Compounds 
WIWAM D. SAVAGE and RONALD T. PFLAUM 
Department of Chemistry, The University of Iowa, Iowa City, Iowa 52242 
CATHERINE HINGA HAUSTEIN* 
Department of Chemistry, Central College, Pella, Iowa 50219 
The room-temperature phosphorescence characteristics of phenothiazine, phenothiazine-based pharmaceuticals, and related compounds 
are presented. It was found that substitution onto the parent ring produces little variation in RTP excitation and emission wavelengths, 
but electron withdrawing substituents reduce RTP intensity. Procedures for the determination of procaine and promethazine in urine and 
clorpromazine in whole blood are presented. 
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Pharmaceuticals belonging to the phenothiazine class are among 
the most widely used drugs in medicine today. Clorpromazine (thor-
azine) and related derivatives have found their major clinical uses as 
tranquilizers. Promethazine (Phenergan), one of the first clinically 
used phenothiazine derivatives, has found use as a sedative and an 
antihistamine. Chlorothiazide, a diuretic, has been used for the treat-
ment of hypertension and congestive heart failure. Procaine, intro-
duced under the trade name Novocain, is primarily used as a local 
anesthetic. It has found wide clinical use because of its low toxicity, 
which is due to rapid destruction by esterases in the tissues and blood, 
preventing the build up of toxic levels. 
Procedures for the determination of drugs in biological fluids 
typically involve the use of an isolation technique such as extraction 
into a non-polar solvent. 1 Methods for the determination of prom-
ethazine and chlorpromazine have been discussed in several review 
articles2-4, and include visible and ultraviolet spectrophotometry, fluo-
rescence, thin-layer and paper chromatography, and gas-liquid chro-
matography. 
Chlorothiazide in urine has most commonly been determined by 
spectrophotometric methods5,6, however, the method is not specific. 
Recently, several phenothiazine drugs have been determined spec-
trophotometrically. 7 High pressure liquid chromatography has been 
used to assay chlorothiazide in blood plasma and urine following 
acidification and extraction into ethyl acetate. 8 Several procedures 
have been published for detecting procaine and other basic amine 
drugs in a blood matrix. These involve an alkaline extraction into ether 
or toluene with subsequent analysis by spectrophotometry9, fluori-
metry 10, and gas-liquid chromatography. 11 Low temperature phos-
phorescence has found application in the analysis of procaine and 
chlorpromazine. 12-14 
Room temperature phosphorescence (RTP) is an important break-
through in the study of phosphors because of its simplicity, selectivity, 
and sensitivity. RTP studies of procaine is, p-aminobenzoic acid 16 and 
diazepam 17 are among the recent applications of RTP to pharmaceuti-
cal analysis, however biological and clincial applications for the tech-
nique are not prevalent in the literature. This study illustrates the 
potential for the anlaysis of such compounds in biological and clinical 
samples. 
*To whom correspondence should be addressed. 
EXPERIMENTAL 
Reagents 
Ethanolic solutions were prepared from absolute alcohol which was 
distilled prior to use, with the first and last 1% being discarded. Stock 
solutions of each pharmaceutical were prepared in 60% alcohol. The 
inorganic salts were of reagent grade quality. Chlorpromazine HCl, 
prochloroperazine edisylate, and trifluoperazine dihydrochloride were 
obtained from Smith, Klein, and French Laboratories; chlorprothixene 
from Hoffman-LaRoche Inc.; chlorothiazide and perphenazine from 
Merck, Sharpe, and Dohme Research Labs; imipramine HCl from 
Bolar Pharmaceutical Co.; procaine hydrochloride from Aldrich 
Chemical Company; promethazine hydrochloride from Wyeth In-
stitute for Medical Research, and thioridazine HCl from Sandoz Inc.. 
All were used as received. Phenothiazine, from Aldrich Chemical 
Company, was recrystallized from ethanol. Urine for biological work 
was obtained from healthy male volunteers. Expired blood plasma and 
citrated whole blood were received from The University of Iowa Blood 
Bank. 
Procedure 
All phosphoroscence measurements were made with an Amino-
Bowman spectrophotofluorimeter with a variable speed Aminco phos-
phoroscope attachment. The system was used without slits except for a 
5 millimeter photomultiplier tube slit. A sample support holder was 
constructed from brass according to previous diagrams. 18 Air and 
moisture were excluded from the sample chamber environment by 
flushing the chamber with nitrogen gas which was first passed 
through a drying tube containing 15 grams of Mg(C104)2 . 
A 1/4 inch (0.625 cm) circle of Schleicher and Schuell 507 filter 
paper was cut using a hole punch. If a heavy atom was incorporated 
into the sample matrix, it was applied by soaking strips of filter paper 
for one minue in one of the following aqueous solutions: 0.2 M CsCl, 
0. 5 M Pb (0Ac)2 , 2 M LiC104 , 0. 5 M Ag N03 , 2 M NaBr, 2 M Nal, 
or 0. 5 M TIE The papers were dried in a desiccator, each tautly 
suspended horizontally between two alligator clips. Once dry, support 
circles of 1/4 inch were prepared. The sample support was then held 
horizontally in an alligator clip and four microliters of the sample 
solution were syringed onto the center of the paper circle. 
Initial drying was accomplished by placing the sample in the 
desiccator for 5 minutes. The dried sample was placed in the RTP 
sample holder and into the nitrogen atmosphere of the phosphoro-
scope. The intensity of the phosphoroscence signal was then obtained 
at the wavelengths of excitation and emission which resulted in the 
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largest signal intensity and the intensity was recorded once a stable 
maximum was achieved. Samples were dried in the sample chamber in 
the presence of ultraviolet light with no adverse effects, with the 
exception of phenothiazine which gave unstable readings unless it was 
dried with the phosphoroscope chopper off. The time required to reach 
a stable signal was approximately ten minutes. The blank for each 
sample was obtained by applying 4 uL of solvent to a 1/4 inch support 
followed by identical treatment as outlined previously. 
Limits of detection correspond to the concentration of sample 
solution which gave a detectable signal equal to twice the background 
blank. The limit of detection in nanograms corresponds to the phos-
phor concentration times the volume analyzed. 
Procedure for Determination of Pharmaceuticals in Whole 
Blood and Plasma 
Drug samples in citrated blood and plasma were prepared by 
pipeting 0. 50 mL of an aqueous stock solution of known concentration 
of the drug, 4.0 mL of absolute ethanol, and 0.50 mL of blood or 
plasma into a 15 mL Pyrex centrifuge tube. A standard solution was 
prepared by placing 0.50 mL stock drug solution, 4.0 mL absolute 
ethanol, and 0. 50 mL water into a centrifuge tube. The blank 
consisted of 1.0 mL water and 4.0 mL absolute ethanol. 
The mixtures were mechanically shaken for 2 minutes, then cen-
trifuged at 8000 rpm for 5 minutes to separate the precipitated 
protein. The resultant liquids were applied to filter paper supports and 
analyzed for phosphorescence. 
Calibration curves were obtained by appropriate dilutions of the 
stock solution of approximately 700 - 100 ppm prior to addition of 
blood and ethanol. 
Procedure for Determination of Pharmaceuticals in Urine 
The following solutions were added to a 0.25 mL sample of urine: 
0.25 mL of stock solution of the drug to be tested in 60% ethanol, 
0. 75 mL of0.01 M pH 5 acetate buffer, and 5.0 mL of ethyl acetate. 
After mixing with a wrist action shaker for 10 minutes the sample was 
centrifuged at 2000 rpm for 3 minutes. The ethyl acetate layer was 
separated, transferred to a clean beaker, and evaporated to dryness at 
60° C in a drying oven. One milliliter of water was added to the residue 
and this solution was placed on a filter which had been treated with the 
appropriate heavy atom. A standard solution was prepared from 0.25 
mL stock solution, 0.25 mL acetate buffer, and 5.0 mL ethyl acetate. 
The blank consisted of 0.50 mL of water, 0. 75 mL of acetate buffer, 
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Fig. 2. Room-temperature phosphorescence spectrum of thioridazine. 
The percentage of drug found in blood or urine was determined by 
dividing the corrected signal intensity (signal minus the blank) of the 
biological sample by the corrected signal intensity of the standard 
solution. 
RESULTS AND DISCUSSION 
Table 1 illustrates the structures of the molecules studied and 
summarizes the room temperature phosphorescence wavelengths. Ex-
perimental factors found to influence phosphorescence of absorbed 
pharmaceuticals at room temperature include the choice of paper 
support, solvent system, elimination of moisture from the sample 
support matrix, and the method of heavy atom application. 19-21 In our 
study, it was found that a very large signal to background ratio was 
obtained with Schleicher and Schuell #507, a very smooth, thin 
paper. The phosphorescence background for this paper was a broad 
continuum with excitation and emission wavelengths around 300 and 
500 nm, respectively. The blank intensity appeared to be constant at 
specified wavelengths from sample to sample. Heavy atom perturbers, 
which increase the sample signals, also increase the background. 
Ratios of signal to background ranged from 160-302 for supports with 
no heavy atom to 55-254 for heavy atom treated supports. 
The phenothiazines had two excitation wavelengths at approx-
imately 263 nm and 325 nm, which corresponded to the two absorp-
tion wavelengths noted for these compounds. 22 Only one emission 
band, at 525 nm, was observed. There appeared to be little difference 
in the excitation and emission wavelengths of phenothiazines with 
various substituent groups in the three and ten positions although the 
intensity of the excitation peak at 263 nm varied somewhat, as 
illustrated by the spectra of perphenazine (Figure 1) and thioridazine 
(Figure 2). A study of the photoelectric spectra of these compounds 
concluded that 3 and 10 substitutions had little effect on the electronic 
character of the aromatic portion of the molecule. 23 It follows that the 
aromatic portion of phenothiazines is primarily responsible for their 
RTP characteristics and this explains the lack of change in the excita-
tion and emission wavelengths. One notable exception was trifluo-
perazine, which showed a greatly reduced RTP intensity when com-
pared with other phenothiazine pharmaceuticals. The trifluromethane 
group is a strong withdrawing group which disrupts the aromaticity of 
the molecule. Oxidation of the phenothiazines, by air and/or hydrogen 
peroxide, to the sulfoxide or the sulfone also destroys the RTP of the 
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amine group in the phenothiazine ring, also did not phosphoresce, 
again indicating that electron withdrawing groups reduce RTP signal 
intensities. Other studies with indoles have also supported this obser-
vation. 24 Chlorprothixene and imipramine are two tranquilizers with 
biological activity similar to the phenothiazine pharmaceuticals, yet 
they also did not exhibit room temperature phosphorescence. Both 
structures contain unconjugated center rings and this would contrib-
ute to their lack of phosphorescence. It is believed that steric, rather 
than electronic effects, are responsible for the pharmaceutical action of 
these compounds, in particular, conformational similarities with 
dopamine. 25 
Thianthrene is a phenothiazine like structure containing two sulfur 
atoms instead of a sulfur and a nitrogen between the phenyl rings. Like 
phenothiazine, thianthrene had an excitation peak at 263 nm, al-
though this was more intense for thianthrene when compared to the 
same concentration of phenothiazine, as shown in Figure 3. This 
indicates that excitation at 263 nm is primarily due to the sulfur atom 
in phenothiazine and like compounds. This is supported by pho-
toelectron data. 23 
The stability of heavy atom treated strips was also studied. It was 
found that dried strips could be stored in a desiccator for up to two 
weeks without compromising reproductibility of the RTP signals (a 
relative standard deviation of3%). As well as improving the sensitivity 
of detection for many phosphors, heavy atoms can also improve the 
selectivity of RTP. Although the RTP of phenothiazine with iodide 
perturbation has been reported26, phenothiazine phosphorescences 
intensely without heavy atom perturbation. This makes RTP a selec-
tive method for the determination of phenothiazine and its derivatives, 
since relatively few compounds phosphoresce strongly without heavy 
atoms. 
A linear relationship exists between RTP intensity and concentra-
tion for promethazine over a concentration range of 1.0 - 870 ug/mL, 
for chlorothiazide from 3.1-43- 700 ug/mL, and for procaine from 
4.2-375 ug/mL. 
In any analysis of pharmaceuticals in biological systems, the pres-
ence of metabolic products of the drugs must be considered. If the 
metabolites of the drug phosphoresce, or if phosphorescent inter-
ferences are present, these substances must be removed, unless spectral 
resolution of the materials is possible. In the case of chlorothiazide, 
absorption from the intestinal tract is rapid. The drug is not metabo-
lized in the kidneys and is excreted in the urine unchanged. The 
concentration of the drug is much higher in urine than in plasma. 27 
Procaine, however, is hydrolysed in the blood by chlorinesterase and 
pseudocholineseterase enzymes, forming p-aminobenzoic acid and 
diethylaminoethanol. Of the initial dose, 50-60% is excreted un-
changed. Approximately 10% of the procaine is metabolised into 
p-aminobenzoic acid and the remainder diethylaminoethanol. 28 
The RTP excitation and emission wavelengths of procaine are 
within 10-20 nm of those of p-aminobenzoic acid and since RTP 
spectra are often broad, spectral resolution of the compounds is 
unlikely. However, the RTP of procaine is enhanced by lead acetate or 
thallium fluoride, while the use of these heavy atoms quenches the 
phosphorescence of p-aminobenzoic acid. Therefore, selective heavy 
atom enhancement may be applicable for the analysis of procaine in the 
presence of its major metabolite. 
Promethazine and procaine were studied to show the application of 
room temperature phosphorescence in the determination of phar-
maceuticals in whole blood. Thiamine, riboflavin, tyrosine, and tryp-
tophan are phosphorescent compounds which could be potential inter-
ferences. To remove these interferences, absolute ethanol was added to 
the blood or plasma to cause immediate precipitation of the protein 
present. Percent recoveries ranged from 106-102% for promethazine 
and 95. 7% to 91.1% for procaine. The procedure allows for excellent 
recovery of the pharmaceuticals. 
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Fig. 3. Room-temperature phosphorescence spectra of thianthrene and 
phenothiazine. 
comparing the phosphorescence intensities of promethazine, chlo-
rothiazide, and chlorpromazine in urine to the same concentration in 
water. Background urine blanks had essentially no phosphorescence 
signals, but the urine matrix reduced the RTP intensities of the 
pharmaceuticals tested to 27 .2-62.8% of the intensities of the drugs in 
water. Constituents present in urine either interfere with the binding 
of the phosphor to the paper, with the interaction of the heavy atoms 
with the desired phosphor, or both. However, a 99.1% recovery of 
chlorothiazide was obtained following extraction with ethyl acetate. 
In conclusion, RTP is a potentially powerful tool for the analysis of 
pharmaceuticals. It is a simple, sensitive, and selective analytical 
technique. RTP excitation wavelengths of the phenothiazine com-
pounds correlate with absorption and photoelectron data. The poten-
tial for utilization of RTP in clinical studies has been shown and as 
more clinical analysts become familiar with the technique, room 
temperature phosphorescence will take its rightful place as a technique 
which compliments fluorimetry. 
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